Skip to main content

Table 4 Baseline characteristics of the study patients with HPV infections

From: Prevalent distribution and survival outcome of HPV infection in patients with early-stage cervical cancer in Hangzhou, China

Characteristic

Mean (SD) or N (%)

HPV16 N (%)

HPV58

HPV18 N (%)

HPV52 N (%)

HR-HPV (13 subtypes)

N (%)

N (%)

P value

HR (95% CI)

Age (years)

 Mean (SD)

48.1 (9.4)

47.0 (9.4)

51.9 (10.0)

47.6 (8.7)

54.1 (11.4)

48.0 (9.5)

0.257

  ≤ 48

795 (55.8)

569 (71.6)

47 (5.9)

66 (8.3)

21 (2.6)

671 (84.4)

0.057

  > 48

630 (44.2)

360 (57.1)

77 (12.1)

43 (6.8)

43 (6.8)

507 (80.5)

  

 FIGO stage

  IA1–IB2

903 (63.4)

590 (65.3)

64 (7.1)

72 (8.0)

39 (4.3)

736 (81.5)

0.146

  IIA1–IIA2

522 (36.6)

339 (64.9)

60 (11.5)

37 (7.1)

25 (4.8)

442 (84.7)

  

SCC-Ag (ng/ml)

 Mean (SD)

4.2 (7.2)

4.3 (7.5)

4.0 (6.3)

4.3 (8.7)

3.7 (7.3)

4.2 (7.3)

0.647

  < 1.5

608 (42.7)

375 (61.7)

47 (7.7)

54 (8.9)

29 (4.8)

483 (79.4)

0.006

1.47 (1.12–1.94)

  ≥ 1.5

817 (57.3)

554 (67.8)

77 (9.4)

55 (6.7)

35 (4.3)

695 (85.1)

  

 Histological grade

  G1

199 (14.0)

134 (67.3)

9 (4.5)

7 (3.5)

7 (3.5)

160 (80.4)

0.364

  G2–G3

1226 (86.0)

795 (64.8)

115 (9.4)

102 (8.3)

57 (4.6)

1018 (83.0)

  

 Deep stromal invasion

  Superficial (< 1/2)

586 (41.1)

388 (66.2)

46 (7.8)

50 (8.5)

19 (3.2)

477 (81.4)

0.319

  Deep (≥ 1/2)

839 (58.9)

541 (64.5)

78 (9.3)

59 (7.0)

45 (5.4)

701 (83.6)

  

 LVSI

  Negative

681 (47.8)

402 (59.0)

64 (9.4)

61 (9.0)

37 (5.4)

541 (79.4)

0.003

1.54 (1.17–2.03)

  Positive

744 (52.2)

527 (70.8)

60 (8.1)

48 (6.5)

27 (3.6)

637 (85.6)

  

 Para-aortic/Pelvic LN

  Negative

1174 (82.4)

760 (64.7)

106 (9.0)

92 (7.8)

54 (4.6)

969 (82.5)

0.854

  Positive

251 (17.6)

169 (67.3)

18 (7.2)

17 (6.8)

10 (4.0)

209 (83.3)

  

 Postoperative therapy

  None

523 (36.7)

332 (63.5)

41 (7.8)

36 (6.9)

24 (4.6)

420 (80.3)

0.081

  Yes

902 (63.3)

597 (66.2)

83 (9.2)

73 (8.1)

40 (4.4)

758 (84.0)

  

Total cases

1425

929 (65.1)

124 (8.7)

107 (7.7)

64 (4.5)

1178 (82.6)

  
  1. FIGO International Federation of Gynecology and Obstetrics, HR-HPV high risk human papillomavirus, HR hazard rate, LN lymph node, LVSI lymph-vascular space invasion, SCC-Ag serum squamous cell carcinoma antigen